Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia [7]

Acta Oncologica

Volumn 45, Issue 3, 2006, Pages 346-349

  Stapnes, Camilla ^a,b   Ryningen, Anita ^a,b   Gjertsen, Bjørn Tore ^a,b   Bruserud, Øystein ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ANTILEUKEMIC AGENT; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; MICROSOMAL AMINOPEPTIDASE; PREDNISOLONE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BLADDER CANCER; CASE REPORT; DUODENUM ULCER; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; NEUROTOXICITY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED, 80 AND OVER; AMINOPHYLLINE; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PLATELET COUNT; TRETINOIN; VALPROIC ACID;

EID: 33646421647     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500482233     Document Type: Letter

References (12)

1. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Hass R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-9.
2. Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101-9.
3. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005;104:2717-25.
4. Raffoux E, Chaibi P, Dombret H, Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005;90:986-8.
5. Zhou DC, Kim SH, Ding W, Schultz C, Warrell RP Jr, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002;99:1356-63.
6. Yang XJ, Gregoire S. Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol 2005;25:2873-84.
7. Seiter K, Feldman EJ, Dorota Halicka H, Deptala A, Traganos F, Burke HB, et al. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia. Br J Haematol 2000;108:40-7.
8. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, et al. In vivo activation of cAMP signalling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 2002;196:1373-80.
9. Ryningen A, Apelseth T, Hausken T, Bruserud Ø. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy. Platelets 2006, in press.
10. Chaoui D, Chakroun T, Robert F, Rio B, Belhocine R, Legrand O, et al. Reticulated platelets: A reliable measure to reduce prophylactic platelet transfusions after intensive chemotheray. Transfusion 2005;45:766-72.
11. Huo X, Zhang J. Important roles of reversible acetylation in the function of hematopoietic transcription factors. J Cell Mol Med 2005;9:103-12.
12. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005;65:2537-41.